MedTrace Logo

Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy

NCT03351556 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2022-08-22

No results posted yet for this study

Summary

1. Determine the "dose-response" relationship between a cash transfer amount and HIV viral suppression at 6 months
2. Identify the most effective cash transfer size to increase the proportion of people living with HIV infection (PLHIV) retained in care and with suppressed viral load (\<1000 copies/ml) after 6 months. (This amount will be further evaluated in a cluster randomized trial in Phase 2).

Conditions

  • HIV/AIDS
  • Adherence, Medication
  • Adherence, Patient

Interventions

BEHAVIORAL

Active Arm 1

Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.

BEHAVIORAL

Active Arm 2

Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Rasello

    collaborator INDUSTRY

  • Health for a Prosperous Nation

    collaborator OTHER

  • Management and Development for Health in Tanzania

    collaborator UNKNOWN

  • University of California, Berkeley

    lead OTHER

Principal Investigators

  • Sandra I McCoy, PhD · University of California, Berkeley

  • Prosper Njau, MD, MPH · Health for a Prosperous Nation and Ministry of Health, Community Development, Gender, Elderly, and Children

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-24
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03351556 on ClinicalTrials.gov